Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766812 | 0.71 | NOTUM (0.42) | NOTUMTSHR | |
| SCHEMBL1559450 | 0.71 | PDPK1 (0.42) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL12906161 | 0.69 | NOTUM (0.59) | NOTUMTSHR | |
| SCHEMBL102331 | 0.69 | PDPK1 (0.59) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL30632310 | 0.67 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL28154527 | 0.67 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL30534095 | 0.67 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL31556353 | 0.67 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1TSHR | |
| SCHEMBL13801151 | 0.67 | NOTUM (0.42) | NOTUMTSHRCDC7DBF4 | |
| SCHEMBL967548 | 0.67 | PDPK1 (0.38) | PDPK1LOXL2CYP2A6HSP90AA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | claimed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | claimed |
| CN-107089975-A | Thiazole salt compounds containing 1,3,4 oxadiazolyls and preparation method and application | 贵州大学 | 2017-08-25 | — | — | CN | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | NOTUM 3541/4885PDPK1 4730/4885LOXL2 3313/4885 |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | NOTUM 3205/4885PDPK1 4849/4885LOXL2 1262/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | NOTUM 3451/4885PDPK1 4848/4885LOXL2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.